Pay in 4 interest-free payments of $5.33 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Eligibility is typically based on criteria such as: Exposure to a brand-name GLP-1 medication Medically confirmed gallbladder disease (gallstones or cholecystitis) requiring cholecystectomy Onset of symptoms closely following drug exposure, with ER visits or hospitalization if severe No documented prior gallbladder disease or other conditions explaining the obstruction The patients Ozempic exposure occurred before the March 2022 label update Patients who meet these criteria and are well documented may have a case
Its essential to save these medical records and reports if you plan to file an Ozempic lawsuit
2020;34:e23531
Extended exposure during storage is not
In rare cases, your provider may recommend additional in-person testing or support available in your local area
Oral semaglutide is a prescription GLP-1 medication taken as a daily tablet that may support weight loss by helping the body better regulate appetite and food intake
